Univariate analysis of association with acute GVHD
| Univariate analysis . | Cumulative incidence, % . | P . |
|---|---|---|
| Donor sex (male vs female) | 36 vs 37 | .04 |
| Patient sex (male vs female) | 30 vs 42 | .003 |
| Sex pairing mismatched (no vs yes) | 35 vs 40 | .03 |
| Female D to male R (no vs yes) | 37 vs 35 | .08 |
| Male D to female R (no vs yes) | 33 vs 45 | .016 |
| Donor median age (40 y or less vs more than 40 y) | 37 vs 36 | .04 |
| Patient median age (42 y or less vs more than 42 y) | 28 vs 45 | .0004 |
| Donor CMV serology (− vs +) | 35 vs 41 | .03 |
| Patient CMV serology (− vs +) | 37 vs 37 | .08 |
| Stage of disease (early vs advanced) | 36 vs 36 | .09 |
| CD34+selection method | ||
| Ceprate | 40 | |
| Isolex | 39 | |
| CliniMacs | 30 log-rank χ2 = 0.45 | .8 |
| Cryopreservation, yes vs no | 28 vs 40 | .06 |
| Median CD34+ cells × 106/kg, 4 or less vs more than 4 | 26 vs 43 | .02 |
| CD34+ cells × 106/kg | ||
| 2 or less; n = 47 | 21 | |
| More than 2 to 4; n = 118 | 35 | |
| More than 4; n = 150 | 43 log-rank χ2= 8.7 | .01 |
| Median CD3+ cells × 106/kg (0.15 or less vs more than 0.15) | 27 vs 42 | .02 |
| CD3+ cells × 106/kg | ||
| 0.05 or less; n = 62 | 18 | |
| More than 0.05 to 0.1; n = 81 | 35 | |
| More than 0.1; n = 172 | 44 log-rank χ2 = 9.8 | .007 |
| CD34+ and CD3+ cells (× 106/kg) | ||
| CD34 4 or less and CD3 0.1 or less; n = 47 | 9 | |
| CD34 more than 4 or CD3 more than 0.1; n = 152 | 36 | |
| CD34 more than 4 and CD3 more than 0.1; n = 116 | 45 log-rank χ2 = 15.7 | .0004 |
| Conditioning regimen (no TBI vs TBI) | 27 vs 43 | .01 |
| GVHD prohylaxis | ||
| CsA | 42 | |
| CsA + PDN | 37 | |
| CsA + MTX | 24 log-rank χ2 = 4.8 | .09 |
| Median 500 N/μL (14 or fewer d vs more than 14 d) | 37 vs 34 | .5 |
| Median 20 000 P/μL (15.5 or fewer d vs more than 15.5 d) | 39 vs 36 | .7 |
| Univariate analysis . | Cumulative incidence, % . | P . |
|---|---|---|
| Donor sex (male vs female) | 36 vs 37 | .04 |
| Patient sex (male vs female) | 30 vs 42 | .003 |
| Sex pairing mismatched (no vs yes) | 35 vs 40 | .03 |
| Female D to male R (no vs yes) | 37 vs 35 | .08 |
| Male D to female R (no vs yes) | 33 vs 45 | .016 |
| Donor median age (40 y or less vs more than 40 y) | 37 vs 36 | .04 |
| Patient median age (42 y or less vs more than 42 y) | 28 vs 45 | .0004 |
| Donor CMV serology (− vs +) | 35 vs 41 | .03 |
| Patient CMV serology (− vs +) | 37 vs 37 | .08 |
| Stage of disease (early vs advanced) | 36 vs 36 | .09 |
| CD34+selection method | ||
| Ceprate | 40 | |
| Isolex | 39 | |
| CliniMacs | 30 log-rank χ2 = 0.45 | .8 |
| Cryopreservation, yes vs no | 28 vs 40 | .06 |
| Median CD34+ cells × 106/kg, 4 or less vs more than 4 | 26 vs 43 | .02 |
| CD34+ cells × 106/kg | ||
| 2 or less; n = 47 | 21 | |
| More than 2 to 4; n = 118 | 35 | |
| More than 4; n = 150 | 43 log-rank χ2= 8.7 | .01 |
| Median CD3+ cells × 106/kg (0.15 or less vs more than 0.15) | 27 vs 42 | .02 |
| CD3+ cells × 106/kg | ||
| 0.05 or less; n = 62 | 18 | |
| More than 0.05 to 0.1; n = 81 | 35 | |
| More than 0.1; n = 172 | 44 log-rank χ2 = 9.8 | .007 |
| CD34+ and CD3+ cells (× 106/kg) | ||
| CD34 4 or less and CD3 0.1 or less; n = 47 | 9 | |
| CD34 more than 4 or CD3 more than 0.1; n = 152 | 36 | |
| CD34 more than 4 and CD3 more than 0.1; n = 116 | 45 log-rank χ2 = 15.7 | .0004 |
| Conditioning regimen (no TBI vs TBI) | 27 vs 43 | .01 |
| GVHD prohylaxis | ||
| CsA | 42 | |
| CsA + PDN | 37 | |
| CsA + MTX | 24 log-rank χ2 = 4.8 | .09 |
| Median 500 N/μL (14 or fewer d vs more than 14 d) | 37 vs 34 | .5 |
| Median 20 000 P/μL (15.5 or fewer d vs more than 15.5 d) | 39 vs 36 | .7 |
D indicates donor; R, recipient; CMV, cytomegalovirus; TBI, total body irradiation; Bu, busulfan; CsA, cyclosporine A; PDN, prednisone; MTX, methotrexate; N, neutrophils; and P, platelets.